SCHEMBL3963485

SCHEMBL3963485

NC(=O)c1cccc2sc(-c3nc(NCCC4CCNCC4)ncc3Cl)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.40
RPS6KB1 P23443 1/20 0.40
CHRM1 P11229 1/20 0.37
CHEK1 O14757 11/20 0.37
KDM1A O60341 1/20 0.37
CNR2 P34972 1/20 0.36
MAPK8 P45983 1/20 0.35
CCNT1 O60563 2/20 0.35
CCNK O75909 2/20 0.35
CDK9 P50750 2/20 0.35
CDK12 Q9NYV4 2/20 0.35
CDK7 P50613 1/20 0.35
CCNH P51946 1/20 0.35
MNAT1 P51948 1/20 0.35
FLT3 P36888 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
PRKCQ Q04759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3961504 0.90 TYRO3 (0.40) CHRM1CHEK1KDM1ACNR2CCNT1
Hydrochloric Acid SCHEMBL3966674 0.90 TYRO3 (0.40) CHRM1CHEK1KDM1ACNR2CCNT1
Hydrochloric Acid SCHEMBL3961743 0.89 FGFR1 (0.38) AURKACHEK1MAPK8FLT3CDK2
SCHEMBL3972472 0.86 KDM1A (0.40) CHEK1KDM1ACCNT1CCNKCDK9
SCHEMBL3964106 0.86 TYRO3 (0.41) CHRM1CHEK1KDM1ACNR2CCNT1
SCHEMBL4084390 0.85 AURKA (0.39) AURKARPS6KB1CHEK1FLT3
Hydrochloric Acid SCHEMBL3965521 0.85 TYRO3 (0.41) CHRM1CHEK1KDM1ACNR2CCNT1
Hydrochloric Acid SCHEMBL3958211 0.83 FGFR1 (0.44) PRKCQ
Hydrochloric Acid SCHEMBL3964437 0.82 KDM1A (0.41) CHEK1KDM1ACCNT1CCNKCDK9
SCHEMBL3961594 0.81 TYRO3 (0.40) CHRM1CHEK1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG AURKA 174/4885RPS6KB1 302/4885CHRM1 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.